Bright Minds Biosciences Inc. (DRUG)

Bright Minds Biosciences Statistics

Total Valuation

DRUG has a market cap or net worth of $793.06 million. The enterprise value is $727.51 million.

Market Cap	793.06M
Enterprise Value	727.51M

Important Dates

The last earnings date was Tuesday, February 10, 2026, after market close.

Earnings Date	Feb 10, 2026
Ex-Dividend Date	n/a

Share Statistics

DRUG has 9.79 million shares outstanding. The number of shares has increased by 48.78% in one year.

Current Share Class	9.79M
Shares Outstanding	9.79M
Shares Change (YoY)	+48.78%
Shares Change (QoQ)	+7.30%
Owned by Insiders (%)	16.49%
Owned by Institutions (%)	51.58%
Float	6.61M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	12.18
P/TBV Ratio	12.18
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 57.37, with a Debt / Equity ratio of 0.00.

Current Ratio	57.37
Quick Ratio	56.59
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-442.41

Financial Efficiency

Return on equity (ROE) is -26.98% and return on invested capital (ROIC) is -15.92%.

Return on Equity (ROE)	-26.98%
Return on Assets (ROA)	-15.72%
Return on Invested Capital (ROIC)	-15.92%
Return on Capital Employed (ROCE)	-21.02%
Weighted Average Cost of Capital (WACC)	0.12%
Revenue Per Employee	n/a
Profits Per Employee	-$556,655
Employee Count	26
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +133.22% in the last 52 weeks. The beta is -0.75, so DRUG's price volatility has been lower than the market average.

Beta (5Y)	-0.75
52-Week Price Change	+133.22%
50-Day Moving Average	82.93
200-Day Moving Average	56.26
Relative Strength Index (RSI)	48.08
Average Volume (20 Days)	94,636

Short Selling Information

The latest short interest is 491,033, so 5.02% of the outstanding shares have been sold short.

Short Interest	491,033
Short Previous Month	524,789
Short % of Shares Out	5.02%
Short % of Float	7.43%
Short Ratio (days to cover)	3.94

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-13.69M
Pretax Income	-14.47M
Net Income	-14.47M
EBITDA	n/a
EBIT	-13.69M
Earnings Per Share (EPS)	-$1.99

Balance Sheet

The company has $64.95 million in cash and $76,507 in debt, with a net cash position of $64.87 million or $6.63 per share.

Cash & Cash Equivalents	64.95M
Total Debt	76,507
Net Cash	64.87M
Net Cash Per Share	$6.63
Equity (Book Value)	65.12M
Book Value Per Share	8.36
Working Capital	65.06M

Cash Flow

Operating Cash Flow	-9.49M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

DRUG does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-48.78%
Shareholder Yield	-48.78%
Earnings Yield	-1.82%
FCF Yield	n/a

Analyst Forecast

The average price target for DRUG is $124.00, which is 49.67% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$124.00
Price Target Difference	49.67%
Analyst Consensus	Strong Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on July 14, 2023. It was a reverse split with a ratio of 1:5.

Last Split Date	Jul 14, 2023
Split Type	Reverse
Split Ratio	1:5

Scores

Altman Z-Score	n/a
Piotroski F-Score	1